Literature DB >> 12668883

Effects of prolactin on cloned human T-lymphocytes.

Zeynep Dogusan1, Nele Martens, Piet Stinissen, Niels Hellings, Nathalie Demotte, Robert Hooghe, Elisabeth Hooghe-Peters.   

Abstract

To evaluate the possible role of prolactin (PRL) in T-lymphocytes, we monitored gene induction in one cytotoxic T-lymphocyte (CTL) clone derived from a patient with hemochromatosis and in several T-helper clones generated from a normal donor and a patient with multiple sclerosis. The CTL clone expressed conventional PRL receptor (PRLR), and PRL induced the expression of suppressor of cytokine signaling-3 (SOCS-3) and increased the expression of SOCS-2 and cytokine-inducible src homology-2 containing protein (CIS, another member of the SOCS family). As is the case in granulocytes, expression of a conventional receptor for PRL could not be shown by polymerase chain reaction analysis on three helper clones. In addition, as in granulocytes, PRL modulated the expression of genes such as the interferon-regulatory factor-1, inducible nitric oxide synthase, CIS, and SOCS-2. These effects were also elicited with ovine PRL and could be prevented by anti-PRL antibodies. Thus, the use of clones allowed the detection of direct effects of PRL on T-cells, even when these have few or no detectable PRLR, confirming that human T-lymphocytes are targets for PRL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668883     DOI: 10.1385/endo:20:1-2:171

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  31 in total

Review 1.  Effect of prolactin on the antigen presenting function of monocyte-derived dendritic cells.

Authors:  L Matera; M Mori; A Galetto
Journal:  Lupus       Date:  2001       Impact factor: 2.911

Review 2.  Negative regulation of cytokine signaling pathways.

Authors:  H Yasukawa; A Sasaki; A Yoshimura
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Bromocriptine therapy in multiple sclerosis: an open label pilot study.

Authors:  V Bissay; N De Klippel; L Herroelen; E Schmedding; T Buisseret; G Ebinger; J De Keyser
Journal:  Clin Neuropharmacol       Date:  1994-10       Impact factor: 1.592

Review 4.  Prolactin receptor signal transduction in cells of the immune system.

Authors:  C V Clevenger; D O Freier; J B Kline
Journal:  J Endocrinol       Date:  1998-05       Impact factor: 4.286

5.  Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon-gamma by natural killer and T cells.

Authors:  L Matera; M Mori
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

6.  Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11.

Authors:  Z Z Hu; J Meng; M L Dufau
Journal:  J Biol Chem       Date:  2001-08-22       Impact factor: 5.157

Review 7.  Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function.

Authors:  S M Richards; W J Murphy
Journal:  J Neuroimmunol       Date:  2000-09-01       Impact factor: 3.478

8.  Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression.

Authors:  H L Dickensheets; C Venkataraman; U Schindler; R P Donnelly
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

9.  MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination.

Authors:  J Zhang; R Medaer; P Stinissen; D Hafler; J Raus
Journal:  Science       Date:  1993-09-10       Impact factor: 47.728

10.  A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum.

Authors:  T Tanaka; R P Shiu; P W Gout; C T Beer; R L Noble; H G Friesen
Journal:  J Clin Endocrinol Metab       Date:  1980-11       Impact factor: 5.958

View more
  1 in total

1.  Serum Prolactin Levels in Multiple Sclerosis, Neuromyelitis Optica, and Clinically Isolated Syndrome Patients.

Authors:  Recai Türkoğlu; Murat Giriş; Mehmet Gencer; Uğur Akcan; Arda Örçen
Journal:  Noro Psikiyatr Ars       Date:  2016-12-01       Impact factor: 1.339

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.